EGFR and carcinoma of esophagus: A commonly proposed molecular target is epidermal growth factor receptor (EGFR), a plasma membrane-bound receptor overexpressed by >67% of oesophageal primary tumours.2 In addition, EGFR overexpression correlates with poor patient survival following chemoradiotherapy3 and radioresistance.4 Unfortunately, clinical trials of EGFR inhibitors have demonstrated limited benefit to date.5 Hence, there remains an urgent need to develop new therapeutics active towards EGFR-overexpressing oesophageal cancers.